Reg IV. A Candidate Marker of Hormone Refractory Metastatic Prostate Cancer
Abstract
In our previous in situ hybridization studies of prostate tissue arrays, ReglV was shown to be strongly expressed by a majority of metastatic hormone refractory tumors (HRPC) and weaker ReglV expression was found in a subset of primary tumors but not expressed by normal tissue. Our goal is to better understand the role of ReglV in prostate cancer progression and to determine its possible use as a diagnostic marker for early and metastatic prostate cancers. We have developed and affinity purified a polyclonal anti-ReglV that has successfully been tested by immunohistochemistry on positive and negative controls. In vitro studies show cells overexpressing ReglV have a growth advantage but not in vivo. However Reg IV knockdown experiment showed that Reg IV may be important in promoting prostate tumor growth during the transition from hormone dependent to hormone refractory status.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 2008
- Accession Number
- ADA479740
Entities
People
- Robert E. Reiter
Organizations
- University of California, Los Angeles